DERISQ Trademark

Trademark Overview

On Thursday, August 7, 2025, a trademark application was filed for DERISQ with the United States Patent and Trademark Office. The USPTO has given the DERISQ trademark a serial number of 99325158. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Friday, January 23, 2026. This trademark is owned by GATC Health Corp. The DERISQ trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Chemical analysis services; Use of proprietary artificial intelligence on a contract basis with customers to analyze drug molecules using genomic and other biological data with respect to the likelihood of a successful FDA clinical trial of such molecule's safety and efficacy, including potential side effects and toxicity, and, if potential deficiencies are identified, the use of such artificial intelligence to assist in the tailoring of such clinical trials in order to remedy such deficiencies; includes the circumstance in which a clinical trial has already been performed unsuccessfully, the revision of the clinical trial protocol to remedy the deficiency.
derisq

General Information

Serial Number99325158
Word MarkDERISQ
Filing DateThursday, August 7, 2025
Status645 - FINAL REFUSAL - MAILED
Status DateFriday, January 23, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Pseudo MarkDE RISK
Goods and ServicesChemical analysis services; Use of proprietary artificial intelligence on a contract basis with customers to analyze drug molecules using genomic and other biological data with respect to the likelihood of a successful FDA clinical trial of such molecule's safety and efficacy, including potential side effects and toxicity, and, if potential deficiencies are identified, the use of such artificial intelligence to assist in the tailoring of such clinical trials in order to remedy such deficiencies; includes the circumstance in which a clinical trial has already been performed unsuccessfully, the revision of the clinical trial protocol to remedy the deficiency.

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 7, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGATC Health Corp
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92614
US

Trademark Events

Event DateEvent Description
Thursday, August 7, 2025NEW APPLICATION ENTERED
Thursday, August 7, 2025APPLICATION FILING RECEIPT MAILED
Tuesday, December 16, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, December 21, 2025ASSIGNED TO EXAMINER
Tuesday, December 23, 2025NON-FINAL ACTION WRITTEN
Tuesday, December 23, 2025NON-FINAL ACTION E-MAILED
Tuesday, December 23, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 5, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 5, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 5, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 23, 2026FINAL REFUSAL WRITTEN
Friday, January 23, 2026FINAL REFUSAL E-MAILED
Friday, January 23, 2026NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, February 26, 2026TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, February 26, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 26, 2026TEAS/EMAIL CORRESPONDENCE ENTERED

Related Keywords

derisq clinical such trial potential deficiencies remedy artificial intelligence identified toxicity